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Summary Tumour localisation of anti-tumour antibodies varies greatly between patients. Factors which may
be responsible for this have been investigated in 56 patients with colorectal carcinoma with a view to
improving radioimmunotherapy. Thirty-seven to seventy-four MBq of 1254- labelled mouse monoclonal
antibody to CEA, was given intravenously and tumour resected 70-480 h later. Percentage injected
activity kg-' (% inj.act kg-') in tumour, was inversely correlated with the time interval between injection and
operation (P = 0.004). To assess the influence of other parameters on localisation, patients were divided into
two time groups according to time interval between injection and operation, 70-120 h (n = 33) and 144-480 h
(n = 23). In neither group was there a significant correlation of % inj.act kg-' with time. The % inj.act kg-' in
tumour showed a significant correlation with that in the blood for both groups (P = 0.005 and P = 0.01).
There was no significant correlation for either time group between % inj.act kg- ' in tumour and serum CEA
values, the per cent of tumour cells positive for CEA and vascularity. Tumour to blood ratios varied
considerably (range 0.3-28.5:1) suggesting that factors other than time and persistence of activity in the blood
contribute to efficient targeting. Tumour to blood ratios were inversely correlated with % inj.act kg- ' in blood
for the 70-120 h group (P = 0.007), and were positively correlated with % inj.act kg-' in tumour (P = 0.012).
Autoradiography showed that antibody localised predominantly on tumour cells but was distributed
heterogeneously, was not solely related to the expression of antigen and in some cases accumulated in necrotic
more than viable areas of tumour. Penetration of antibody into malignant acinar structures was poor and
CEA-positive cells closer to the blood supply were targeted to a greater extent than distant cells. Preoperative
administration of radiolabelled antibody to CEA may be helpful in selecting patients with favourable
localisation for radioimmunotherapy.
Localisation of intravenously administered anti-tumour
antibodies in tumours is used clinically in immunoscinti-
graphy (IS), radioimmunoguided surgery (RIGS) and anit-
body targeted therapy of cancer (Begent et al., 1985; Martin
et al., 1988; Begent, 1990). There is great variability in
uptake of antibody in individual tumours in patients and the
factors influencing this are poorly understood. Distribution
of injected antibodies within tumours is not uniform (Griffith
et al., 1988; Pedley et al., 1990). The causes of heterogeneity
of intratumour distribution of antibody have been addressed
by Cobb, 1989 and Jain and Baxter, 1988 and the conse-
quences of nonuniformity of antibody binding on tumour
dose in radioimmunotherapy are discussed by Humm and
Cobb, 1990. Most autoradiographic studies of the distribu-
tion of antibody at the microscopic level have been confined
to human tumour xenograft model systems in nude mice
(Pedley et al., 1990; Sampsel et al., 1990). In patients, tumour
and normal tissues from resected specimens collected follow-
ing radioimmunoguided surgery with '25I-labelled antibody
(Blair et al., 1990), allows the microdistribution of antibody
to be investigated. A number of factors may putatively
influence antibody localisation, including antigen
heterogeneity, tumour vascularisation and rate of clearance
of antibody from the circulation.
This paper attempts to clarify how factors affecting bio-
distribution of antibody may be important in modifying
existing agents or designing new ones for antibody targeted
therapy, IS and RIGS. The preoperative administration of
radiolabelled antibody for use with RIGS (Blair et al., 1990;
Tuttle et al., 1988) provides an opportunity to obtain tissue
samples from patients receiving antibody which are suitable
for studying the relevant parameters. Autoradiography, com-
bined with immunohistochemical demonstration of CEA and
vascular endothelium, shows the relationship of localised
antibody to the target antigen and tumour vasculature. In-
formation about the extravasation, penetration, passage and
retention of antibody within tumours and factors affecting
localisation is essential if new or modified agents are to be
designed for efficient antibody directed therapy of cancer.
Patients and methods
Fifty-six patients with colorectal carcinoma gave informed
consent to enter the trial. Antibody uptake in thyroid was
blocked by administration of potassium iodide and potas-
sium perchlorate. Patients were tested for skin allergy as
previously described (Begent et al., 1986). 0.4 mg of IgGI
mouse monoclonal antibody (A5B7) to CEA (Harwood et
al., 1986) was radiolabelled with of 1251, by the Chloramine T
method over ice, to a specific activity of 93-185 MBq mg-'
and injected intravenously. Patients underwent surgery
70-480 h (mean 135) later.
Gamma counting ofradioactivity
Resected specimens were collected and representative samples
from the tumour, normal mucosa, and lymph nodes were
taken. Where present any sites of metastatic tumour were
dissected out. Blood samples were taken on the day of oper-
ation. Tissue and blood samples were weighed, dissolved in
2 ml of 7 M potassium hydroxide and counted for gamma
radioactivity in a Compugamma (LKB). The percentage
injected activity per kilogram of tissue was calculated (Pedley
et al., 1987). Adjacent pieces of tissue were fixed in 10%
formalin and processed for routine histology.
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Immunohistochemistryfor CEA antigen and tumour vessels
Four micron sections of formalin-fixed paraffin processed
tumour tissue were incubated with two mouse monoclonal
antibodies to different epitopes on CEA, F3E3 and A5B7
(Harwood et al., 1986) in an avidin biotin peroxidase tech-
nique (Southall et al., 1990). As a measure of antigen density
in the tumour the number ofCEA positive cells were counted
in 50 randomly chosen fields (x 200) and expressed as a
percentage of total cells (per cent CEA + ve cells). In addi-
tion to tumour cells colorectal adenocarcinomas are partly
composed of fibrovascular stroma which does not produce
CEA. To account for this, in the same fields, the area of
tumour (T) vs stroma (S) was calculated using an image
analyser (Joyce-Loebl) by drawing around areas of tumour
cells and expressed as a percentage (T/(T + S) x 100). A
measure of the percentage of tumour containing CEA was
calculated from (per cent CEA +ve cells) x (T/
(T + S) x 100). The differentiation, site, amount of necrosis,
and the pushing or infiltrative nature of the tumour were
recorded. Necrotic areas were measured using the image
analyser and expressed as a per cent of the tumour area.
Necrotic material confined within complete, viable glands
was not included. Antigen distribution within tumours, dem-
onstrated by immunohistochemistry, was assessed in terms of
binding to membrane or cytoplasm of cells and intensity of
reaction was scored on an arbitrary scale of + to + + +.
Tumour blood vessels were demonstrated immunohisto-
chemically as described above using an antibody to vascular
endothelium, QBend/10 (Sankey et al., 1990). Twenty-five
fields (x 200) from areas of viable tumour were randomly
selected in each patient. The percentage of the field occupied
by blood vessels was calculated, using the image analyser to
draw around the internal circumference of each vessel.
Autoradiography
Autoradiographic studies were performed in 12 cases in
which sufficient radioactive counts were obtained in tumour
(in excess of 100,000 counts per minutegram-'). The techni-
que was as previously described (Pedley et al., 1990). Before
covering with autoradiographic film, serial sections of
tumour and normal tissues were immunohistochemically
stained with an antibody to CEA and with QBend/10 as
previously described in the manuscript. Control sections,
incubated with biotinylated anti-mouse antibody and avidin
biotin peroxidase alone, were always negative. Sections were
counterstained after development of the autoradiographs
with haematoxylin only.
Statistical analysis
Correlations of the per cent injected activity in tumour and
tumour to blood ratios, with blood levels of radioactivity,
serum CEA, tumour CEA, vascularity and the time interval
between injection and operation were investigated. Correla-
tions of parameters with numerical values were performed
using the non parametric Spearman Rank Correlation Test.
Correlations of per cent injected activity in tumour with site
and the pushing or infiltrative nature of the tumour were
performed using the Mann-Whitney U test.
Results
Tumour characteristics and antibody localisation
The histological and immunohistochemical (distribution of
CEA) characteristics of the tumours, the % inj.act kg-' in
tumour, tumour to blood ratios and time interval between
injection and operation are shown in Table I. The wide range
of % inj.act kg-' in tumour (0.342-10.55) is illustrated.
Most of the tumours were moderately differentiated. The
amount of differentiation did not influence tumour uptake of
radiolabelled antibody. In most patients, immunohisto-
chemistry showed antigen in tumour to be both cytoplasmic
and membrane associated with similar intensity of reaction.
In those few patients whose tumours showed a differential
intensity in reaction between cytoplasm and membrane there
seemed to be no association with % inj.act kg-' in tumour or
tumour to blood ratios. In 29/56 necrotic areas constituted
less than 5% of total area and in 12/56 necrotic areas consti-
tuted 10% or more. These tumours were not associated with
higher or lower per cent injected activities.
Figure 1 shows the distribution of tumour uptake
(inj.act kg-') of 125I anti-CEA in the 56 patients. Whilst 40 of
the 56 patients had % inj.actkg' of less than 2% they
achieved mean tumour to normal bowel ratios of 3.5.
Although patients with more than 2% injected activities in
tumour were less frequent they were associated with higher
tumour to normal bowel ratios.
Factors affecting % inj.actkg-' in tumour
Table II shows the correlations of % inj.act kg-' in tumour
with eight factors. The % inj.act kg-' in tumour was positively
correlated with % inj.act kg-' in blood and, for the early
time group, with tumour to blood ratio. The other factors
had no significant effect.
Figure 2 shows a significant inverse relationship between
% inj.act kg-' in tumour and the time interval between injec-
tion and operation in the 56 patients (P = 0.004). Becuase of
this relationship of tumour uptake with time in the whole
patient group, in order to investigate the influence of other
parameters, the patients were divided into two subgroups
according to the time interval between injection and oper-
ation. These were 70-120 h (n = 33) and 144-480 h
(n = 23). In neither group was there a significant dependence
upon time (P = 0.48 and P = 0.07).
There was a significant correlation between % inj.act kg-'
in tumour and % inj.act kg-' in blood in the 70-120 h
(P = 0.005) and the 144-480 h (P = 0.01) groups.
Tumour to blood ratio
There was a significant inverse relationship between
% inj.act kg-' in blood and the tumour to blood ratio
(P = 0.007) in the 70-120 h group. In the 144-480 h group
the relationship did not achieve significance (P = 0.08). There
was also a significant correlation between % inj.actkg-' in
tumour and tumour to blood ratios (P = 0.012) for the
70-120 h group. In the 144-480 h group the correlation was
not significant (P = 0.11).
Otherfactors
The relationship between % inj.act kg-' in tumour and
serum CEA levels was not significant in either the early
(P = 0.63) or late (P = 0.56) time point group. However, two
patients with values in excess of 2,000tg 1' showed low
% inj.act kg-' in tumour (0.608 and 0.,529) and low tumour
to blood ratios (0.6 and 1.2). There was no relationship
between % inj.act kg-' in tumour and density of CEA in
viable tumour in either the early (P = 0.44) or late
(P = 0.71) time point group. There was no significant rela-
tionship between % inj.act kg-' in tumour and vascularity in
viable tumour in either the early (P = 0.39) or late (P = 0.28)
time point group. However, in one patient, increased localisa-
tion in an ovarian metastasis compared with the primary
colonic tumour (12:1) was associated with an increase in
vascularity (4.8:1), in the ovarian vs the colonic tumour. The
density of CEA, demonstrated immunohistochemically in the
tumour at each site, appeared similar. There was no associa-
tion between the % inj.act kg-' in tumour and the site (colon
or rectum), for the early (P = 0.66) or late (P = 0.14) time
point groups. In the 144-480 h group the per cent injected
activities were higher in the patients tumours with an
infiltrative rather than pushing front (P = 0.02).FACTORS INFLUENCING ANTIBODY LOCALISATION 827
Table I Tumour histology, antigen distribution and antibody localisation characteristics
Histology
WD/MD/PD +
Mucoid areas
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
WD/MD/PD +
Mucoid areas
MD/PD +
Mucoid areas
Villous Adenoma
MD
MD
MD + Mucoid and
Papillary areas
MD
MD
MD
MD
MD
MD + Mucoid and
Papillary areas
MD
MD
MD
PD
MD
MD
MD + Mucoid
areas
MD
MD
PD
MD/PD
WD Arising in
Adenoma
Tubulovillous
Adenoma
MD
MD
Necrosis
<5%
Nil
10%
<5%
<5%
<5%
<5%
<5%
10%
<5%
<5%
<5%
<5%
<5%
Nil
Nil
<5%
<5%
<5%
<5%
<5%
<5%
5%
10%
5%
Nil
Nil
<5%
10%
10%
10%
<5%
10%
10%
<5%
Nil
Nil
10%
Nil
CEA-Cytoplasm
IMembrane
Cyto + + +
Mem + + +
Cyto + +-+ +
Mem + +-+ ++
Cyto + + +
Mem +
Cyto + + +
Mem + + +
Cyto +++
Mem + + +
Cyto + + +
Mem + + +
Cyto + + +
Mem + + +
Cyto +
Mem + + +
Cyto +++
Mem + + +
Cyto + +
Mem + + +
Cyto + + +
Mem + + +
Cyto + + +
Mem + + +
Cyto + + +
Mem + + +
Cyto +
Mem + + +
Cyto + + +
Mem + + +
Cyto + + +
Mem + + +
Cyto + +
Mem + + +
Cyto + +-+ +
Mem + +-+ ++
Cyto + + +
Mem + +
Cyto + + +
Mem + + +
Cyto +++
Mem +
Cyto + + +
Mem +
Cyto + +
Mem + +
Cyto +-+++
Mem +-+ ++
Cyto +
Mem + +
Cyto + +
Mem + +
Cyto + + +
Mem + + +
Cyto + + +
Mem + +
Cyto + +-+ ++
Mem +-+ ++
Cyto +
Mem + + +
Cyto + + +
Mem + + +
Cyto +--++
Mem +-+ ++
Cyto + +
Mem + +
Cyto + + +
Mem +
Cyto + + +
Mem + + +
Cyto +-++
Mem +-+ ++
Cyto +
Mem +
Cyto + +
Mem + + +
Cyto + +
Mem + + +
% inj.actkg-' Tumour to Time interval
in tumour
1.135
1.671
1.371
7.765
0.407
0.524
1.296
1.997
1.021
0.803
1.398
0.342
5.111
1.589
0.419
9.304
3.549
3.085
0.744
1.414
0.567
0.704
1.484
0.985
1.678
1.769
3.504
0.884
3.712
1.817
10.55
0.608
0.529
1.325
0.542
2.141
2.13
1.332
1.144
blood ra
4.49
1.62
5.44
4.64
1.71
3.80
ND
1.16
24.90
4.72
7.17
20.12
7.59
ND
0.39
3.19
1.71
2.83
1.55
1.71
3.73
5.72
28.54
2.44
4.37
1.09
15.23
0.77
5.58
1.98
8.79
0.62
1.21
ND
3.17
2.26
1.87
9.72
4.09
tio Inj-op (hours)
216
96
120
144
120
168
144
96
144
168
192
480
96
168
88
120
96
120
168
70
144
168
96
114
120
96
144
72
91
96
89
114
88
168
168
91
96
120
120
Table I - (continued overleaf)
Patient no.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
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Table I - continued
Histology
MD
MD
MD/PD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD + Mucoid
areas
PD
MD
MD/PD + Mucoid
areas
PD
Necrosis
5%
<5%
<5%
<5%
5%
5%
5%
<5%
5%
5%
20%
<5%
10%
38%
Nil
5%
5%
CEA-Cytoplasm
/Membrane
Cyto +
Mem +++
Cyto + +
Mem +++
Cyto + + +
Mem + + +
Cyto + + +
Mem +++
Cyto + + +
Mem +++
Cyto +
Mem +++
Cyto + + +
Mem + + +
Cyto + + +
Mem +++
Cyto + + +
Mem ++
Cyto + + +
Mem +++
Cyto + +
Mem +
Cyto + +-+ + +
Mem ++-+++
Cyto + + +
Mem +++
Cyto + + +
Mem +++
Cyto + + +
Mem +++
Cyto + + +
Mem +++
Cyto + + +
Mem +
Differention: WD = Well differentiated;
done.
MD = Moderately differentiated; PD = Poorly differentiated; ND = Not
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Figure 1 Distribution of tumour uptake of 125I anti-CEA in 56
patients. Tumour to normal bowel ratios are given as mean
values for each group.
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Figure 2 Tumour uptake of 1251 anti-CEA. Relation to time (all
patients). n = number of data points. P = correlation coefficient.
Line of regression is plotted.
Table II Correlation coefficients (P values) for putative determining factors for % injact kg-' in tumour -~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Time interval % inj.act kg-' Tumour to Serum Tumour Pushing/a
Patient Group (inj-op) in blood blood ratio CEA CEA Vascularity Sitea Infiltrative
70-120 h 0.48 0.005 0.012 0.63 0.45 0.39 0.66 0.21
(n = 33) ((n = 32) (n = 32) (n = 24) (n = 33) (n = 20) (n = 32) (n = 30)
144-480 h 0.07 0.01 0.11 0.56 0.72 0.3 0.14 0.02
(n =23) (n = 18) (n = 18) (n = 12) (n =23) (n =23) (n =23) (n = 23)
n = number of available data sets. All P values were obtained using Spearman Rank Correlation Test except aMann Whitney U test.
Patient no.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
% inj.actkg-'
in tumour
5.48
1.285
2.032
0.598
0.319
0.445
6.911
0.562
1.172
1.234
6.322
0.912
0.899
0.754
0.786
2.313
4.969
Tumour to
blood ratio
5.25
7.98
8.95
ND
2.40
4.01
8.38
ND
3.84
9.64
6.87
1.37
3.53
18.39
1.56
9.93
ND
Time interval
Inj-op (hours)
96
96
168
168
168
120
120
168
144
96
96
114
144
210
115
S
144
72
4 It
1
I
I
I
I
c
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Autoradiography
Figures 3-5 relate to the autoradiographic results. Figure 3a
shows localisation of autoradiographic grains associated with
radiolabelled antibody predominantly in tumour cells, with
grains overlying malignant acini. The fibrovascular stroma
contains fewer grains. Figure 3b shows normal colonic crypts
which contain no grains. Figures 4a and 4b counterstained
with antibody to CEA, show the localisation of radiolabelled
antibody in cells expressing CEA (4a) and an absence of
grains in an area of tumour with low levels of target antigen
(4b). However in other areas there are grains associated with
malignant glands in which there is only focal positivity for
CEA. Figure 5 (counterstained with antibody to vascular
endothelium) shows an accumulation of grains in necrotic
more than viable areas of tumour. In some tumours there
was selective targeting of isolated CEA positive cells in the
fibrovascular stroma with adjacent malignant acini virtually
unlabelled. Antibody penetration in some areas of tumours
was poor. Autoradiography in some areas showed grains on
the basement membrane aspect of the tumour, in close
proximity to the fibrous stroma. Deeper tumour cells appeared
less well targeted (data not shown).
In no sections was there any obvious retention of radio-
labelled antibody in vascular endothelium nor associated
with the cells or serum protein within blood vessels. This is
consistent with clearance of antibody from the circulation at
time points corresponding to these patients resections (70 h
or more post injection). In some patients accumulations of
grains were greatest nearest to blood vessels. However,
planar sections give limited three dimensional information
about the spatial relationships of blood vessels with glan-
dular structures and tumour cells. Therefore, any conclusions
about the access of antibody to tumour cells from the cir-
culation are difficult to make. These autoradiographic results
illustrate the extent to which radiolabelled antibody to CEA
is distributed heterogeneously in colonic adenocarcinomas.
Figure 3 Autoradiographs showing localisation of radiolabelled
antibody in a, tumour (mag x 150) and b, normal colonic mucosa
(mag x 100). Counterstained with haematoxylin and eosin.
Figure 4 Autoradiographs showing localisation of radiolabelled
antibody in a, an area of tumour expressing CEA (mag x 240)
and b, an area of tumour with poor expression of CEA
(mag x 240). Sections counterstained with an antibody to CEA
and haematoxylin.
Figure 5 Autoradiographs of a section of tumour counterstained
with an antibody QBend/10 and haematoxylin, showing
accumulation of radiolabelled antibody in necrosis (mag x 150).
Discussion
Correlation of per cent injected activity in tumour with a
variety of factors has yielded a number of observations.
Whilst no consistent evidence was found that density of
antigen expression, tumour vascularisation or moderate
elevation of serum CEA influenced tumour localisation, there
were some incidental findings. In the two patients with serum
CEA values in excess of 2,000 ytg 1' (patients 32 and 33) the
% inj.act kg-' in tumour and tumour blood ratios were830 G.M. BOXER et al.
amongst the lowest recorded. Given that standard man con-
tains 3.1 litres of plasma (MIRD Tables-International Com-
mission on Radiological Protection (October 1974), Report
ofthe Task Group on Reference Man, Pergamon Press), then
2,000jig 1' of CEA represents a total of 6.2 mg of CEA
antigen. Assuming that intact IgG antibody (molecular
weight 150,000) binds serum CEA (molecular weight 200,000)
on a one to one basis then at a serum level of 129pg 1', the
concentration of administered antibody (0.4 mg) and antigen
would be the same. Clearly not all the antibody can be
complexed with antigen since some patients with values of
300 still showed selective uptake in the tumour. But these
findings support the hypothesis (Pedley et al., 1989; Martin &
Halpern, 1984) that high levels of circulating antigen can
affect the potential of antibodies to localise efficiently in
tumours.
In one patient (27) when comparing the ovarian metastasis
with the primary colonic tumour, there was shown to be an
increase in the per cent area occupied by blood vessels (4.8:1)
which mirrored a corresponding increase in per cent injected
activity (12:1). The absence of any correlation between
% inj.act kg-' in tumour and density of CEA in tumour,
suggests that penetration into, and/or retention of antibody
within malignant glandular structures and on tumour cells, is
sub-optimal. This is illustrated by the autoradiographic
studies showing that antibody localisation is heterogeneous
and not solely related to the presence of antigen.
High levels of circulating antibody predicted high levels of
antibody localisation in tumour. However, the considerable
variation in tumour to blood ratios (0.31-28.54) suggests
that there are other factors which contribute to efficient
targeting. Tumour to blood ratios correlated significantly
with % inj.act kg-' in the tumour, and inversely with per
cent injected activity in the blood, in the 70-120 h time point
group. Therefore patients who achieve high tumour to blood
ratios do so as both a function of high % inj.act kg-' in
tumour and clearance of antibody from the circulation. This
suggests that in a proportion of patients at least there is
specific antibody targeting. This is supported by data
accumulated in our department from patients undergoing
radioimmunotherapy with '"'I antibody to CEA (A5B7).
These patients are scanned at serial time points from 3 h post
injection and blood samples are collected at corresponding
time points. It is possible to quantitate the % inj.act kg-' in
both tumour and blood (Begent et al., 1989; Green et al.,
1990) and tumour to blood ratios can be calculated for each
patient over a time course. Patients with high % inj.act kg'
in tumour tend to have high tumour to blood ratios.
Whilst the data presented here is from single time points,
these observations have implications for antibody directed
therapy. Applebaum et al., 1987 and DeNardo et al., 1988
have shown that radiation doses to blood and bone marrow
are related. Since myelosuppression is the principal toxicity in
radioimmunotherapy, tumour to blood ratio gives an indica-
tion of likely therapeutic ratio. The results show that tumour
to blood ratios may be improved by rapid clearance of
antibody from the circulation. This can be manipulated by
giving antibody fragments such as Fab' and Fv which may
be cleared more rapidly from the circulation than whole
antibody. These smaller molecules may also penetrate more
efficiently into tumour giving a further advantage (Sutherland
et al., 1987). Second antibody, directed against the anti-
tumour may also be used to accelerate clearance from the
bloodstream (Begent et at., 1989).
These data also suggest that only patients likely to have
high % inj.act kg-'in tumour should be selected for therapy.
This could be done at radioimmunoguided surgery or by
quantitative imaging studies before therapy. If murine
antibodies are used human anti-mouse antibodies may develop
before therapy, but this can be prevented by use of chimeric
or humanised antibodies.
Autoradiographic results suggest that localisation of
antibody to CEA in tumours is heterogeneous and whilst it is
usually related to the presence of antigen, antibody is not
retained by all antigen positive cells. In some cases antibody
was retained more in necrotic than in viable areas. These
data are from tumour removed 70 or more hours after
injection and distribution may be different at earlier times.
Steis et al., 1990, suggest that uptake and retention of
antibodies which recognise predominantly cytoplasmic
antigens, in colonic carcinomas, may be indicative ofpools of
antigen released from dead or dying cells. Sampsel et al.,
1990, have shown by autoradiography, that in a colonic
adenocarcinoma xenograft model, B72.3 antibody localised
in proportions increasing with time in necrotic rather than
viable areas of the tumour over a 10 day time course. This
phenomenon has important consequences for antibody
directed radiotherapy since tumour to blood ratios increased
with time in the 50 patients in this study (P = 0.007). High
tumour to blood ratios are considered important in increas-
ing the therapeutic ratio in radioimmunotherapy. However,
at later times after antibody injection the remaining antibody
may be in necrotic tissue having cleared from viable tumour
areas.
Autoradiography showed that antibody does not always
penetrate efficiency into malignant tumour acini even if they
are antigen rich and in some areas only isolated CEA
positive cells are labelled. The finding in the 144-480 h
group, that there were higher per cent injected activities in
the patients tumours with an infiltrative rather than pushing
front, suggests that the cellular organisation of malignant
glandular structures may influence antibody uptake. This
may be due to the basement and basolateral membranes being
less well defined in tumours of an infiltrative nature. The
diffusion of antibody molecules across membranes and into
glandular structures is desirable if they are to reach the
luminal surface to be retained where CEA is concentrated in
high amounts. Humm and Cobb, 1989 have considered the
consequences that heterogeneity of radiolabelled antibody
binding has for tumour cell sterilisation. They particularly
considered the importance of whether the isotope is extracel-
lular, membrane bound or internalised. They showed that
membrane bound antibody has markedly enhanced potential
for energy deposition in the nuclei compared with uniform
source distribution throughout the tissue.
Lack of penetration into, and poor retention within, many
viable tumour areas highlights the need to explore agents
with better properties of diffusion or ones which may help to
exploit the tumour's own cellular, uptake and transport
mechanisms. Better understanding of the reasons for the
variation in % inj.act kg-' is needed and it is evident that
there are additional parameters to those described in this
paper. A knowledge of the extent to which antibody localisa-
tion in tumours is either facilitated or impeded is important
in order to help design new or modify existing agents for
targeted therapy.
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